Helicon Therapeutics is a development-stage biotechnology firm working on new therapies for memory loss and other cognition disorders. The company's research and development efforts focus on a protein that controls the signal pathway key to forming long-term memories. Scientists working for Helicon Therapeutics discovered the protein while studying the fruit fly genome. The company is working on drugs to not only maintain memory but also possibly to prevent memories from forming in the first place. Lead drug candidate HT-0712 has shown the ability to improve long-term memory in rats. Other candidates are in early stages of development.

Trimeris, Inc. was founded in 1993 and is based in Durham, North Carolina. Trimeris, Inc., a biopharmaceutical company, engages primarily in the commercialization of a class of fusion inhibitors for antiviral drug treatments. Its fusion inhibitors impair viral fusion, a complex process by which viruses attach to, penetrate, and infect host cells. The company offers FUZEON, a human immunodeficiency virus (HIV) fusion inhibitor and a 36-amino acid synthetic peptide that binds to a key region of an HIV surface protein called gp41 under a collaboration with F. Hoffmann-La Roche Ltd. Its FUZEON inhibitor blocks HIV viral fusion by interfering with certain structural rearrangements within gp41 that are required for HIV to fuse to and enter a host cell. FUZEON is approved in the United States, Canada, and the European Union. The company also holds TRI-1144, a next generation fusion inhibitor candidate that completed Phase I clinical trials.

AERES Biomedical Ltd. company was founded in 1999. AERES Biomedical develops therapeutic antibodies. The biopharmaceutical research company has developed more than 20 antibody candidates though collaborative partnerships with other biotech and pharmaceutical companies, many of which are in clinical trial stages. ABC-48 (an antibody for the treatment of deep vein thrombosis) and ABC-120 (an antibody for treating malaria) are two of the company's top candiates. AERES' products target debilitating and life-threatening illnesses, such as infectious, inflamatory, and cardiovascular diseases.

Access Pharmaceuticals, Inc. was founded in 1988 and is based in Dallas, Texas. Access Pharmaceuticals, Inc. (Access) is a biopharmaceutical company focused on developing products based upon its nanopolymer chemistry technologies and other drug delivery technologies. As of December 31, 2008, the Company has one approved product, one product at Phase III of clinical development, four products in Phase II of clinical development, and four products in pre-clinical development. On January 4, 2008, the Company acquired Somanta Pharmaceuticals, Inc. On February 25, 2009, Access acquired MacroChem Corporation.

Idenix Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of drugs for the treatment of human viral and other infectious diseases in the United States and Europe. The company's primary product includes Tyzeka/Sebivo for the treatment of hepatitis B virus. It also develops IDX899, a non-nucleoside reverse transcriptase inhibitor (NNRTI), for the treatment of human immunodeficiency virus (HIV)/ acquired immune deficiency syndrome (AIDS). In addition, Idenix Pharmaceuticals, Inc. focuses on the development of drugs for the treatment of hepatitis C virus. It has a license agreement with GlaxoSmithKline to develop, manufacture, and commercialize its NNRTI compounds, including IDX899 for the treatment of HIV/AIDS. The company was founded in 1998 and is headquartered in Cambridge, Massachusetts. Idenix Pharmaceuticals, Inc. is a subsidiary of Novartis Pharma AG.

NutraCea is a health science company that has intellectual property that allows the Company to process and convert rice bran into a nutritious ingredient, stabilized rice bran that has applications in various food products and as components of formulations that have applications for treatment modalities in nutritional supplementation. It is also used as a stand-alone product that can be sold through non-related entities with distribution into the market place, both in the United States and internationally. These products include food supplements and medical foods. The Company operates in two segments: the NutraCea segment, which manufactures and distributes ingredients primarily derived from SRB, and the Irgovel segment, which consists of its rice-bran oil and fatted and de-fatted SRB manufacturing subsidiary in Pelotas, Brazil. In November 2009, the Company filed a voluntary petition for protection under Chapter 11 of the United States Bankrupt Code.

Cobra Biomanufacturing offers contract research and manufacturing services to the biopharmaceutical industry. It develops genetic research supplies for use in preclinical research and early clinical trial stages. The company helps its global clients navigate through regulatory requirements while designing and manufacturing novel proteins, viruses, and other cellular products for use in drug development and manufacturing processes. Clients use Cobra Biomanufacturing's products and technologies to develop gene-based disease therapies and vaccine products.

Streck, Inc. company was founded in 1971 and is based in Omaha, Nebraska. Streck, Inc. develops and manufactures hematology, chemistry, and immunology products for the clinical laboratory in the United States, Japan, and internationally. It offers controls for automated hematology instruments, and hematology controls, reagents, and support products; controls for immunophenotyping by flow cytometry; A1c-Cellular, a blood cellular control product for instruments measuring HbA1c; and UA-Cellular for IQ that provides a thorough evaluation of the iQ instrument's ability to identify and quantify white blood cells, red blood cells, non-squamous epithelial cells, and crystals. The company also provides hematology reagents, which include diluents, lysing agents, enzymatic cleansers, and detergents; quality control devices, including the red spirit thermometers with scales in 1/2-degree increments to monitor refrigerators, freezers, and incubators/room temperatures; and automated erythrocyte sedimentation rate (ESR) analyzers. In addition, it offers technical services.

Taconic Farms, Inc. company provides research rodents and related products and services to research facilities and medical laboratories in Asia, Europe, and North America. Taconic's rats and mice are the workhorses of the biomedical industry and specially bred to be disease-free or genetically modified to exhibit certain traits to help researchers develop new therapies for human disease. Other divisions within the company offer monoclonal antibody production, and drug- and animal-safety testing. It has operations in Denmark, Germany, and the US. Family-owned Taconic was founded in 1952 by Robert Phelan.

ProStrakan Group plc company specializes in those areas, but also focuses on therapies for women's health and issues relating to the ageing male. ProStrakan's marketed products include brain tumor treatment Bélustine and bone therapy Adcal. Products in development include therapies to treat alopecia and hypogonadism. ProStrakan markets its products to more than 10 countries in the EU, and has applied for FDA approval of pain medication Abstral in the US. ProStrakan company was founded as Strakan in 1995 by Chairman Harry Stratford and changed its name to ProStrakan when it merged with ProSkelia. Warbug Pincus and Aventis Pharma each hold majority shares in the company.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.